Prelude Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Prelude Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$163K	Buy	+26,200	New	+$113K	0.01%	1019
2024 Q4	–	Sell	-91,250	Closed	-$758K	–	1427
2024 Q3	$758K	Buy	+91,250	New	+$789K	0.05%	467
2023 Q2	–	Sell	-10,968	Closed	-$154K	–	1274
2023 Q1	$154K	Sell	10,968 -1,500	-12%	-$21.5K	0.01%	904
2022 Q4	$178K	Buy	+12,468	New	+$196K	0.01%	996

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Prelude Capital Management's MRVI Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Maravai LifeSciences (MRVI) in Q2 2026: 26,200 shares worth $163K. The stake represents 0.01% of the portfolio and ranks #1019 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in MRVI as recently as Q3 2024.

Prelude Capital Management first reported a position in MRVI in Q4 2022 and has held it in 4 quarters since. The position peaked at $758K in Q3 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Prelude Capital Management held 26,200 shares of Maravai LifeSciences worth $163K as of Q2 2026.
Maravai LifeSciences was a new Prelude Capital Management position in Q2 2026.
Maravai LifeSciences made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1019 holding.
Prelude Capital Management first reported a position in Maravai LifeSciences in Q4 2022 and has held it in 4 quarters since.
Prelude Capital Management's Maravai LifeSciences position peaked at $758K in Q3 2024.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.